Top

Diabetology & Metabolic Syndrome

Published in:

Open Access 01-12-2024 | Lung Cancer | Review

Association between insulin resistance, metabolic syndrome and its components and lung cancer: a systematic review and meta-analysis

Authors: Jingxuan Liu, Rui Wang, Song Tan, Xiaohu Zhao, Aihua Hou

Published in: Diabetology & Metabolic Syndrome | Issue 1/2024

Abstract

Background

A growing body of evidence points to the association between insulin resistance (IR), metabolic syndrome (MetS) and its components and lung cancer incidence, but remains controversial and unknown.

Methods

A systematic search was conducted through PubMed, Embase, Cochrane Library, the China National Knowledge Infrastructure (CNKI) and Wanfang databases for the corresponding studies. Each study reported the risk estimate and 95% confidence intervals (CI) for lung cancer, and a fixed effects model or random effects model was used for outcome.

Results

We included 31 publications involving 6,589,383 people with 62,246 cases of lung cancer. Diabetes mellitus (DM) (RR = 1.11, 95% CI 1.06–1.16, P = 0.000) and IR (RR = 2.35, 95% CI 1.55–3.58, P = 0.000) showed a positive association with lung cancer risk. BMI (RR = 0.66, 95% CI 0.54–0.81, P = 0.000) and HDL-C (RR = 0.88, 95% CI 0.79–0.97, P = 0.010) were negatively correlated with lung cancer. MetS(RR = 0.99, 95% CI 0.90–1.09, P = 0.801), TC (RR = 0.93, 95% CI 0.81–1.06, P = 0.274), TG (RR = 0.99, 95% CI 0.88–1.12,P = 0.884), LDL-C (RR = 1.01, 95% CI 0.87–1.16, P = 0.928), hypertension (RR = 1.01, 95% CI 0.88–1.15, P = 0.928), FBG (RR = 1.02, 95% CI 0.92–1.13, P = 0.677) and obesity (RR = 1.11, 95% CI 0.92–1.35, P = 0.280) were not associated with lung cancer.

Conclusion

Our study showed that the risk of lung cancer is correlated with DM, IR, BMI, and HDL-C. Timely control of these metabolic disorders may have a positive effect on preventing lung cancer.

Trial registration Our study has been registered in the Prospective Register of Systematic Reviews (PROSPERO), ID: CRD42023390710.

Available only for authorised users

Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644.CrossRefPubMed

NCD Countdown 2030 collaborators. NCD Countdown 2030: worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet. 2018;392(10152):1072–88. https://doi.org/10.1016/S0140-6736(18)31992-5.CrossRef

Freeman AM, Pennings N. Insulin resistance. In: Freeman AM, editor. StatPearls. Treasure Island: StatPearls Publishing; 2022.

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRefPubMed

Wood DE, Kazerooni EA, Aberle D, et al. NCCN guidelines insights: lung cancer screening, version 1.2022. J Natl Compr Canc Netw. 2022;20(7):754–64. https://doi.org/10.6004/jnccn.2022.0036.CrossRefPubMed

Scherübl H. Metabolic syndrome and cancer risk. Dtsch Med Wochenschr. 2022;147(16):1068–77. https://doi.org/10.1055/a-1868-9164.CrossRefPubMed

Xu J, Ye Y, Wu H, et al. Association between markers of glucose metabolism and risk of colorectal cancer. BMJ Open. 2016;6(6): e011430. https://doi.org/10.1136/bmjopen-2016-011430.CrossRefPubMedPubMedCentral

Saboori S, Rad EY, Birjandi M, Mohiti S, Falahi E. Serum insulin level, HOMA-IR and prostate cancer risk: a systematic review and meta-analysis. Diabetes Metab Syndr. 2019;13(1):110–5. https://doi.org/10.1016/j.dsx.2018.08.031.CrossRefPubMed

Hernandez AV, Pasupuleti V, Benites-Zapata VA, Thota P, Deshpande A, Perez-Lopez FR. Insulin resistance and endometrial cancer risk: a systematic review and meta-analysis. Eur J Cancer. 2015;51(18):2747–58. https://doi.org/10.1016/j.ejca.2015.08.031.CrossRefPubMed

10.

Zhao J, Zhang Q, Yang Y, Yao J, Liao L, Dong J. High prevalence of thyroid carcinoma in patients with insulin resistance: a meta-analysis of case-control studies. Aging (Albany NY). 2021;13(18):22232–41. https://doi.org/10.18632/aging.203529.CrossRefPubMed

11.

Hernandez AV, Guarnizo M, Miranda Y, et al. Association between insulin resistance and breast carcinoma: a systematic review and meta-analysis. PLoS ONE. 2014;9(6): e99317. https://doi.org/10.1371/journal.pone.0099317.ADSCrossRefPubMedPubMedCentral

12.

López-Jiménez T, Duarte-Salles T, Plana-Ripoll O, Recalde M, Xavier-Cos F, Puente D. Association between metabolic syndrome and 13 types of cancer in Catalonia: a matched case-control study. PLoS ONE. 2022;17(3): e0264634. https://doi.org/10.1371/journal.pone.0264634.CrossRefPubMedPubMedCentral

13.

Osaki Y, Taniguchi S, Tahara A, Okamoto M, Kishimoto T. Metabolic syndrome and incidence of liver and breast cancers in Japan. Cancer Epidemiol. 2012;36(2):141–7. https://doi.org/10.1016/j.canep.2011.03.007.CrossRefPubMed

14.

Inoue M, Noda M, Kurahashi N, et al. Impact of metabolic factors on subsequent cancer risk: results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev. 2009;18(3):240–7. https://doi.org/10.1097/CEJ.0b013e3283240460.CrossRefPubMed

15.

Rapp K, Schroeder J, Klenk J, et al. Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults in Austria. Diabetologia. 2006;49(5):945–52. https://doi.org/10.1007/s00125-006-0207-6.CrossRefPubMed

16.

Kuriki K, Hirose K, Tajima K. Diabetes and cancer risk for all and specific sites among Japanese men and women. Eur J Cancer Prev. 2007;16(1):83–9. https://doi.org/10.1097/01.cej.0000228404.37858.40.CrossRefPubMed

17.

Johnson JA, Bowker SL, Richardson K, Marra CA. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia. 2011;54(9):2263–71. https://doi.org/10.1007/s00125-011-2242-1.CrossRefPubMed

18.

Park HJ, Joh HK, Choi S, Park SM. Type 2 diabetes mellitus does not increase the risk of lung cancer among never-smokers: a nationwide cohort study. Transl Lung Cancer Res. 2019;8(6):1073–7. https://doi.org/10.21037/tlcr.2019.11.01.CrossRefPubMedPubMedCentral

19.

Yang WS, Yang Y, Yang G, et al. Pre-existing type 2 diabetes and risk of lung cancer: a report from two prospective cohort studies of 133,024 Chinese adults in urban Shanghai. BMJ Open. 2014;4(7): e004875. https://doi.org/10.1136/bmjopen-2014-004875.CrossRefPubMedPubMedCentral

20.

Wang X, Li QL, Liu Y. Correlation between type 2 diabetes mellitus and lung cancer. Oncol Prog. 2016;14(7):693–5. https://doi.org/10.11877/j.issn.1672-1535.2016.14.07.26. (In Chinese).CrossRef

21.

Leiter A, Charokopos A, Bailey S, et al. Assessing the association of diabetes with lung cancer risk. Transl Lung Cancer Res. 2021;10(11):4200–8. https://doi.org/10.21037/tlcr-21-601.CrossRefPubMedPubMedCentral

22.

Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005;293(2):194–202. https://doi.org/10.1001/jama.293.2.194.CrossRefPubMed

23.

Stattin P, Björ O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care. 2007;30(3):561–7. https://doi.org/10.2337/dc06-0922.CrossRefPubMed

24.

Luo J, Chlebowski R, Wactawski-Wende J, Schlecht NF, Tinker L, Margolis KL. Diabetes and lung cancer among postmenopausal women. Diabetes Care. 2012;35(7):1485–91. https://doi.org/10.2337/dc11-2108.CrossRefPubMedPubMedCentral

25.

Chodick G, Heymann AD, Rosenmann L, et al. Diabetes and risk of incident cancer: a large population-based cohort study in Israel. Cancer Causes Control. 2010;21(6):879–87. https://doi.org/10.1007/s10552-010-9515-8.CrossRefPubMed

26.

Stocks T, Rapp K, Bjørge T, et al. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med. 2009;6(12): e1000201. https://doi.org/10.1371/journal.pmed.1000201.CrossRefPubMedPubMedCentral

27.

Hao B, Yu M, Sang C, Bi B, Chen J. Dyslipidemia and non-small cell lung cancer risk in Chinese population: a case-control study. Lipids Health Dis. 2018;17(1):278. https://doi.org/10.1186/s12944-018-0925-z.CrossRefPubMedPubMedCentral

28.

Li X. Related factors of type 2 diabetes mellitus patients with lung cancer. Guangxi Medical University. 2012. https://kns.cnki.net/kcms/detail/detail.aspx?FileName=1012349108.nh&DbName=CMFD2012 (In Chinese). Accessed 14 July 2023

29.

Lyu Z, Li N, Wang G, et al. Independent and joint associations of blood lipids and lipoproteins with lung cancer risk in Chinese males: a prospective cohort study. Int J Cancer. 2019;144(12):2972–84. https://doi.org/10.1002/ijc.32051.CrossRefPubMed

30.

Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med. 2006;166(17):1871–7. https://doi.org/10.1001/archinte.166.17.1871.CrossRefPubMed

31.

Ahn J, Lim U, Weinstein SJ, et al. Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(11):2814–21. https://doi.org/10.1158/1055-9965.EPI-08-1248.CrossRefPubMedPubMedCentral

32.

Kitahara CM, Berrington de González A, Freedman ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011;29(12):1592–8. https://doi.org/10.1200/JCO.2010.31.5200.CrossRefPubMedPubMedCentral

33.

Kucharska-Newton AM, Rosamond WD, Schroeder JC, et al. HDL-cholesterol and the incidence of lung cancer in the Atherosclerosis Risk in Communities (ARIC) study. Lung Cancer. 2008;61(3):292–300. https://doi.org/10.1016/j.lungcan.2008.01.015.CrossRefPubMed

34.

Zhao C. Independent associations between blood lipid profiles and lung cancer risk. Shandong Univ. 2021. https://doi.org/10.27272/d.cnki.gshdu.2021.006868. (In Chinese).CrossRef

35.

Ko S, Yoon SJ, Kim D, Kim AR, Kim EJ, Seo HY. Metabolic risk profile and cancer in Korean men and women. J Prev Med Public Health. 2016;49(3):143–52. https://doi.org/10.3961/jpmph.16.021.CrossRefPubMedPubMedCentral

36.

Strohmaier S, Edlinger M, Manjer J, et al. Total serum cholesterol and cancer incidence in the metabolic syndrome and cancer project (Me-Can). PLoS ONE. 2013;8(1): e54242. https://doi.org/10.1371/journal.pone.0054242.ADSCrossRefPubMedPubMedCentral

37.

Everatt R, Virvičiūtė D, Kuzmickienė I, Tamošiūnas A. Body mass index, cholesterol level and risk of lung cancer in Lithuanian men. Lung Cancer. 2014;85(3):361–5. https://doi.org/10.1016/j.lungcan.2014.07.009.CrossRefPubMed

38.

Petridou ET, Sergentanis TN, Antonopoulos CN, et al. Insulin resistance: an independent risk factor for lung cancer? Metabolism. 2011;60(8):1100–6. https://doi.org/10.1016/j.metabol.2010.12.002.CrossRefPubMed

39.

Argirion I, Weinstein SJ, Männistö S, Albanes D, Mondul AM. Serum insulin, glucose, indices of insulin resistance, and risk of lung cancer. Cancer Epidemiol Biomarkers Prev. 2017;26(10):1519–24. https://doi.org/10.1158/1055-9965.EPI-17-0293.CrossRefPubMedPubMedCentral

40.

Bai B. Blood glucose and insulin resistance in lung cancer patients. Zhengzhou University. 2016. https://d.wanfangdata.com.cn/thesis/ChJUaGVzaXNOZXdTMjAyMzAxMTISB0Q4Mzk1MjIaCGFhc2RlNGd4 (In Chinese). Accessed 15 July 2023

41.

Zhao WF. The level and significance of insulin resistance in patients with lung cancer. Zhengzhou University. 2016. https://kns.cnki.net/KCMS/detail/detail.aspx?dbname=CMFD201701&filename=1016175784.nh. (In Chinese). Accessed 15 July 2023

42.

Tseng CH. Diabetes but not insulin increases the risk of lung cancer: a Taiwanese population-based study. PLoS ONE. 2014;9(7): e101553. https://doi.org/10.1371/journal.pone.0101553.ADSCrossRefPubMedPubMedCentral

43.

Chung KC, Juang SE, Chen HH, et al. Association between metabolic syndrome and colorectal cancer incidence and all-cause mortality: a hospital-based observational study. BMC Gastroenterol. 2022;22(1):453. https://doi.org/10.1186/s12876-022-02505-5.CrossRefPubMedPubMedCentral

44.

Hernández-Pérez JG, Torres-Sánchez L, Hernández-Alcaráz C, et al. Metabolic syndrome and prostate cancer risk: a population case-control study. Arch Med Res. 2022;53(6):594–602. https://doi.org/10.1016/j.arcmed.2022.07.003.CrossRefPubMed

45.

Palmiero P, Maiello M, Cecere A, Ciccone MM. Metabolic syndrome and breast cancer: a dangerous association for postmenopausal women. Acta Biomed. 2021;92(4): e2021177. https://doi.org/10.23750/abm.v92i3.11335.CrossRefPubMedPubMedCentral

46.

Song JL, Li LR, Yu XZ, et al. Association between metabolic syndrome and clinicopathological features of papillary thyroid cancer. Endocrine. 2022;75(3):865–71. https://doi.org/10.1007/s12020-021-02940-6.CrossRefPubMed

47.

Park B. Associations between obesity, metabolic syndrome, and endometrial cancer risk in East Asian women. J Gynecol Oncol. 2022;33(4): e35. https://doi.org/10.3802/jgo.2022.33.e35.CrossRefPubMedPubMedCentral

48.

Esposito K, Chiodini P, Capuano A, et al. Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine. 2013;44(3):634–47. https://doi.org/10.1007/s12020-013-9939-5.CrossRefPubMed

49.

Yu MW, Lin CL, Liu CJ, Yang SH, Tseng YL, Wu CF. Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic Hepatitis B: a large cohort study. Gastroenterology. 2017;153(4):1006-1017.e5. https://doi.org/10.1053/j.gastro.2017.07.001.CrossRefPubMed

50.

Kabat GC, Kim M, Chlebowski RT, et al. A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev. 2009;18(7):2046–53. https://doi.org/10.1158/1055-9965.EPI-09-0235.CrossRefPubMedPubMedCentral

51.

Lee JY, Jeon I, Lee JM, Yoon JM, Park SM. Diabetes mellitus as an independent risk factor for lung cancer: a meta-analysis of observational studies. Eur J Cancer. 2013;49(10):2411–23. https://doi.org/10.1016/j.ejca.2013.02.025.CrossRefPubMed

52.

Sona MF, Myung SK, Park K, Jargalsaikhan G. Type 1 diabetes mellitus and risk of cancer: a meta-analysis of observational studies. Jpn J Clin Oncol. 2018;48(5):426–33. https://doi.org/10.1093/jjco/hyy047.CrossRefPubMed

53.

Yi ZH, Luther Y, Xiong GH, et al. Association between diabetes mellitus and lung cancer: meta-analysis. Eur J Clin Invest. 2020;50(10): e13332. https://doi.org/10.1111/eci.13332.CrossRefPubMed

54.

Luo J, Hendryx M, Qi L, Ho GY, Margolis KL. Pre-existing diabetes and lung cancer prognosis. Br J Cancer. 2016;115(1):76–9. https://doi.org/10.1038/bjc.2016.141.CrossRefPubMedPubMedCentral

55.

Talakatta G, Sarikhani M, Muhamed J, et al. Diabetes induces fibrotic changes in the lung through the activation of TGF-β signaling pathways. Sci Rep. 2018;8(1):11920. https://doi.org/10.1038/s41598-018-30449-y.ADSCrossRefPubMedPubMedCentral

56.

Ding J, Tang J, Chen X, et al. Expression characteristics of proteins of the insulin-like growth factor axis in non-small cell lung cancer patients with preexisting type 2 diabetes mellitus. Asian Pac J Cancer Prev. 2013;14(10):5675–80. https://doi.org/10.7314/apjcp.2013.14.10.5675.CrossRefPubMed

57.

Huang Y, Cai X, Qiu M, et al. Prediabetes and the risk of cancer: a meta-analysis. Diabetologia. 2014;57(11):2261–9. https://doi.org/10.1007/s00125-014-3361-2.CrossRefPubMed

58.

Kirakli EK, Yilmaz U, Yilmaz H, Komurcuoglu B. Fasting blood glucose level in locally advanced non-small cell lung cancer: a new prognostic factor? Horm Cancer. 2018;9(3):188–96. https://doi.org/10.1007/s12672-018-0322-0.CrossRefPubMedPubMedCentral

59.

Yang JR, Chen GC, Xu JY, et al. Fasting blood glucose levels and prognosis in patients with non-small-cell lung cancer: a prospective cohort study in China. Onco Targets Ther. 2019;12:5947–53. https://doi.org/10.2147/OTT.S210103.CrossRefPubMedPubMedCentral

60.

Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z. Lipid metabolism and cancer. J Exp Med. 2021;218(1): e20201606. https://doi.org/10.1084/jem.20201606.CrossRefPubMed

61.

Petrelli F, Cortellini A, Indini A, et al. Association of obesity with survival outcomes in patients with cancer: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(3): e213520. https://doi.org/10.1001/jamanetworkopen.2021.3520.CrossRefPubMedPubMedCentral

62.

Yang Y, Dong J, Sun K, et al. Obesity and incidence of lung cancer: a meta-analysis. Int J Cancer. 2013;132(5):1162–9. https://doi.org/10.1002/ijc.27719.CrossRefPubMed

63.

Duan P, Hu C, Quan C, et al. Body mass index and risk of lung cancer: systematic review and dose-response meta-analysis. Sci Rep. 2015;5:16938. https://doi.org/10.1038/srep16938.ADSCrossRefPubMedPubMedCentral

64.

Zhu H, Zhang S. Body mass index and lung cancer risk in never smokers: a meta-analysis. BMC Cancer. 2018;18(1):635. https://doi.org/10.1186/s12885-018-4543-y.CrossRefPubMedPubMedCentral

65.

Li S, Wang Z, Huang J, Fan J, Du H, Liu L, Che G. Systematic review of prognostic roles of body mass index for patients undergoing lung cancer surgery: does the “obesity paradox” really exist? Eur J Cardiothorac Surg. 2017;51(5):817–28. https://doi.org/10.1093/ejcts/ezw386.CrossRefPubMed

66.

Hastie CE, Padmanabhan S, Slack R, et al. Obesity paradox in a cohort of 4880 consecutive patients undergoing percutaneous coronary intervention. Eur Heart J. 2010;31(2):222–6. https://doi.org/10.1093/eurheartj/ehp317.CrossRefPubMed

67.

Petrelli F, Ghidini A, Cabiddu M, et al. Effects of hypertension on cancer survival: a meta-analysis. Eur J Clin Invest. 2021;51(6): e13493. https://doi.org/10.1111/eci.13493.CrossRefPubMed

68.

Almatrafi A, Thomas O, Callister M, Gabe R, Beeken RJ, Neal R. The prevalence of comorbidity in the lung cancer screening population: a systematic review and meta-analysis. J Med Screen. 2023;30(1):3–13. https://doi.org/10.1177/09691413221117685.CrossRefPubMed

69.

Zeng X, Zeng D, Cheng J, et al. Influence of hypertension on the survival of non-small cell lung cancer patients with type 2 diabetes mellitus. Med Sci Monit. 2020;26: e921676. https://doi.org/10.12659/MSM.921676.CrossRefPubMedPubMedCentral

70.

Liu J, Yang X, Liu X, Xu Y, Huang H. Predictors of readmission after pulmonary resection in patients with lung cancer: a systematic review and meta-analysis. Technol Cancer Res Treat. 2022;21:15330338221144512. https://doi.org/10.1177/15330338221144512.CrossRefPubMedPubMedCentral

71.

Lin X, Lu L, Liu L, et al. Blood lipids profile and lung cancer risk in a meta-analysis of prospective cohort studies. J Clin Lipidol. 2017;11(4):1073–81. https://doi.org/10.1016/j.jacl.2017.05.004.CrossRefPubMed

72.

Gijsberts CM, den Ruijter HM, Asselbergs FW, Chan MY, de Kleijn DP, Hoefer IE. Biomarkers of coronary artery disease differ between Asians and Caucasians in the general population. Glob Heart. 2015;10(4):301-311.e11. https://doi.org/10.1016/j.gheart.2014.11.004.CrossRefPubMed

73.

Chen L, Zhang L, Xian G, Lv Y, Lin Y, Wang Y. 25-Hydroxycholesterol promotes migration and invasion of lung adenocarcinoma cells. Biochem Biophys Res Commun. 2017;484(4):857–63. https://doi.org/10.1016/j.bbrc.2017.02.003. (published correction appears in Biochem Biophys Res Commun. 2020 Oct 20;531(3):440-441; published correction appears in Biochem Biophys Res Commun. 2021 May 28;555:212).CrossRefPubMed

74.

Zhou P, Li B, Liu B, Chen T, Xiao J. Prognostic role of serum total cholesterol and high-density lipoprotein cholesterol in cancer survivors: a systematic review and meta-analysis. Clin Chim Acta. 2018;477:94–104. https://doi.org/10.1016/j.cca.2017.11.039.CrossRefPubMed

75.

Su F, Grijalva V, Navab K, et al. HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer. Mol Cancer Ther. 2012;11(6):1311–9. https://doi.org/10.1158/1535-7163.MCT-11-0905.CrossRefPubMedPubMedCentral

76.

Ruscica M, Botta M, Ferri N, et al. High density lipoproteins inhibit oxidative stress-induced prostate cancer cell proliferation. Sci Rep. 2018;8(1):2236. https://doi.org/10.1038/s41598-018-19568-8.ADSCrossRefPubMedPubMedCentral

77.

Hao B, Bi B, Sang C, et al. Systematic review and meta-analysis of the prognostic value of serum high-density lipoprotein cholesterol levels for solid tumors. Nutr Cancer. 2019;71(4):547–56. https://doi.org/10.1080/01635581.2019.1577983.CrossRefPubMed

78.

Maghlaperidze Z, Kapetivadze V, Tabukashvili R, Lazashvili T, Kuparadze M, Gratiashvili E. The role of insulin-like growth factor-1 and insulin in development of colorectal cancer. Georgian Med News. 2021;315:26–9.

79.

Saisana M, Griffin SM, May FEB. Insulin and the insulin receptor collaborate to promote human gastric cancer. Gastric Cancer. 2022;25(1):107–23. https://doi.org/10.1007/s10120-021-01236-y.CrossRefPubMed

80.

Karlstad O, Starup-Linde J, Vestergaard P, et al. Use of insulin and insulin analogs and risk of cancer: systematic review and meta-analysis of observational studies. Curr Drug Saf. 2013;8(5):333–48. https://doi.org/10.2174/15680266113136660067.CrossRefPubMed

81.

Loftfield E, Freedman ND, Lai GY, et al. Higher glucose and insulin levels are associated with risk of liver cancer and chronic liver disease mortality among men without a history of diabetes. Cancer Prev Res (Phila). 2016;9(11):866–74. https://doi.org/10.1158/1940-6207.CAPR-16-0141.CrossRefPubMed

82.

Kira S, Ito C, Fujikawa R, Misumi M. Increased cancer mortality among Japanese individuals with hyperinsulinemia. Metabol Open. 2020;7:100048. https://doi.org/10.1016/j.metop.2020.100048.CrossRefPubMedPubMedCentral

83.

Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35(11):2402–11. https://doi.org/10.2337/dc12-0336.CrossRefPubMedPubMedCentral

84.

Qiao L, Ma D, Lv H, et al. Metabolic syndrome and the incidence of lung cancer: a meta-analysis of cohort studies. Diabetol Metab Syndr. 2020;12:95. https://doi.org/10.1186/s13098-020-00598-0.CrossRefPubMedPubMedCentral

85.

Wang H, Yan F, Cui Y, Chen F, Wang G, Cui W. Association between triglyceride glucose index and risk of cancer: a meta-analysis. Front Endocrinol (Lausanne). 2023;13:1098492. https://doi.org/10.3389/fendo.2022.109849.CrossRefPubMedPubMedCentral

Title: Association between insulin resistance, metabolic syndrome and its components and lung cancer: a systematic review and meta-analysis
Authors: Jingxuan Liu
Rui Wang
Song Tan
Xiaohu Zhao
Aihua Hou
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Lung Cancer
Lung Cancer
Lung Cancer
Insulins
Insulins
Diabetes
Obesity
Obesity
Published in: Diabetology & Metabolic Syndrome / Issue 1/2024
Electronic ISSN: 1758-5996
DOI: https://doi.org/10.1186/s13098-024-01308-w

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

Cost-effectiveness of semaglutide 2.4 mg in chronic weight management in Portugal

The effects of bupropion alone and combined with naltrexone on weight loss: a systematic review and meta-regression analysis of randomized controlled trials

The Regulate your Sitting Time (RESIT) intervention for reducing sitting time in individuals with type 2 diabetes: findings from a randomised-controlled feasibility trial

A comparison of various insulin resistance indices and the possibility of hypertension in military adults: CHIEF study

Clinical inertia in newly diagnosed type 2 diabetes mellitus among patients attending selected healthcare institutions in Colombia

Cardiovascular outcomes associated with SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cancer: a systematic review and meta-analysis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials